Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | NSCLC | Research

Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer

Authors: Chunfeng Xie, Xu Zhou, Chunhua Liang, Xiaoting Li, Miaomiao Ge, Yue Chen, Juan Yin, Jianyun Zhu, Caiyun Zhong

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

Recently, a variety of clinical trials have shown that apatinib, a small-molecule anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including non-small cell lung cancer (NSCLC). However, the underlying molecular mechanism of apatinib on NSCLC remains unclear.

Methods

MTT, EdU, AO/EB staining, TUNEL staining, flow cytometry, colony formation assays were performed to investigate the effects of apatinib on cell proliferation, cell cycle distribution, apoptosis and cancer stem like properties. Wound healing and transwell assays were conducted to explore the role of apatinib on migration and invasion. The regulation of apatinib on VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling were detected. Furthermore, we collected conditioned medium (CM) from A549 and H1299 cells to stimulate phorbol myristate acetate (PMA)-activated THP-1 cells, and examined the effect of apatinib on PD-L1 expression in macrophages. The Jurkat T cells and NSCLC cells co-culture model was used to assess the effect of apatinib on T cells activation. Subcutaneous tumor formation models were established to evaluate the effects of apatinib in vivo. Histochemical, immunohistochemical staining and ELISA assay were used to examine the levels of signaling molecules in tumors.

Results

We showed that apatinib inhibited cell proliferation and promoted apoptosis in NSCLC cells in vitro. Apatinib induced cell cycle arrest at G1 phase and suppressed the expression of Cyclin D1 and CDK4. Moreover, apatinib upregulated Cleaved Caspase 3, Cleaved Caspase 9 and Bax, and downregulated Bcl-2 in NSCLC cells. The colony formation ability and the number of CD133 positive cells were significantly decreased by apatinib, suggesting that apatinib inhibited the malignant and stem-like features of NSCLC cells. Mechanistically, apatinib inhibited PD-L1 and c-Myc expression by targeting VEGFR2/STAT3 signaling. Apatinib also inhibited PD-L1 expression in THP-1 derived macrophages stimulated by CM from NSCLC cells. Furthermore, apatinib pretreatment increased CD69 expression and IFN-γ secretion in stimulated Jurkat T cells co-cultured with NSCLC cells. Apatinib also promoted ROS production and inhibited Nrf2 and p62 expression, leading to the autophagic and apoptotic cell death in NSCLC. Moreover, apatinib significantly inhibited tumor growth in vivo.

Conclusion

Our data indicated that apatinib induced autophagy and apoptosis in NSCLC via regulating VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling.

Available only for authorised users

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. https://doi.org/10.1016/S0025-6196(11)60735-0.CrossRefPubMed

Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. https://doi.org/10.21037/tlcr.2016.06.07.CrossRefPubMedPubMedCentral

Zhang C, Leighl NB, Wu YL, Zhong WZ. Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 2019;12(1):45. https://doi.org/10.1186/s13045-019-0731-8.CrossRefPubMedPubMedCentral

Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4(1):61. https://doi.org/10.1038/s41392-019-0099-9.CrossRefPubMedPubMedCentral

Daum S, Hagen H, Naismith E, Wolf D, Pircher A. The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer - new combinational approaches and strategies of neovessel inhibition. Front Cell Dev Biol. 2020;8:610903.CrossRefPubMed

Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Translat Med. 2014;2(12):123. https://doi.org/10.3978/j.issn.2305-5839.2014.08.14.CrossRef

Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015;9:6075–81.CrossRefPubMedPubMedCentral

10.

Fathi Maroufi N, Rashidi MR, Vahedian V, Akbarzadeh M, Fattahi A, Nouri M. Therapeutic potentials of Apatinib in cancer treatment: possible mechanisms and clinical relevance. Life Sci. 2020;241:117106. https://doi.org/10.1016/j.lfs.2019.117106.CrossRefPubMed

11.

Liang J, Gu W, Jin J, Zhang H, Chen Z, Tang Y, et al. Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study. Therapeut Adv Med Oncol. 2020;12:1758835920968472.

12.

Zhou C, Wang Y, Zhao J, Chen G, Liu Z, Gu K, et al. Efficacy and biomarker analysis of Camrelizumab in combination with Apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy. Clin Cancer Res. 2021;27(5):1296–304.

13.

Xu Y, Huang Z, Lu H, Yu X, Li Y, Li W, et al. Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. Br J Cancer. 2019;121(8):640–6. https://doi.org/10.1038/s41416-019-0583-6.CrossRefPubMedPubMedCentral

14.

Liang P, Ballou B, Lv X, Si W, Bruchez MP, Huang W, et al. Monotherapy and combination therapy using anti-angiogenic nanoagents to fight cancer. Adv Mater. 2021;33(15):e2005155.

15.

Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, et al. Low-dose Apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. Cancer Immunol Res. 2019;7(4):630–43. https://doi.org/10.1158/2326-6066.CIR-17-0640.CrossRefPubMed

16.

Wang Q, Gao J, Di W, Wu X. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. Cancer Immunol Immunother. 2020;69(9):1781–99. https://doi.org/10.1007/s00262-020-02576-x.CrossRefPubMed

17.

Zheng B, Ren T, Huang Y, Guo W. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Biochem Biophys Res Commun. 2018;495(2):1695–701. https://doi.org/10.1016/j.bbrc.2017.12.032.CrossRefPubMed

18.

Cai X, Wei B, Li L, Chen X, Liu W, Cui J, et al. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression. Int Immunopharmacol. 2020;88:106858. https://doi.org/10.1016/j.intimp.2020.106858.CrossRefPubMed

19.

Yang Y, Wang C, Sun H, Jiang Z, Zhang Y, Pan Z. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma. Cancer Gene Ther. 2021;28(1–2):89–97. https://doi.org/10.1038/s41417-020-0186-7.CrossRefPubMed

20.

Liu Y, Lang F, Yang C. NRF2 in human neoplasm: Cancer biology and potential therapeutic target. Pharmacol Ther. 2021;217:107664. https://doi.org/10.1016/j.pharmthera.2020.107664.CrossRefPubMed

21.

Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. 2010;12(3):213–23. https://doi.org/10.1038/ncb2021.CrossRefPubMed

22.

Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009;137(6):1062–75. https://doi.org/10.1016/j.cell.2009.03.048.CrossRefPubMedPubMedCentral

23.

Ichimura Y, Komatsu M. Activation of p62/SQSTM1-Keap1-nuclear factor erythroid 2-related factor 2 pathway in cancer. Front Oncol. 2018;8:210. https://doi.org/10.3389/fonc.2018.00210.CrossRefPubMedPubMedCentral

24.

Sun X, Li J, Li Y, Wang S, Li Q. Apatinib, a novel tyrosine kinase inhibitor, promotes ROS-dependent apoptosis and autophagy via the Nrf2/HO-1 pathway in ovarian cancer cells. Oxidative Med Cell Longev. 2020;2020:3145182.

25.

Feng H, Cheng X, Kuang J, Chen L, Yuen S, Shi M, et al. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. Cell Death Dis. 2018;9(10):1030. https://doi.org/10.1038/s41419-018-1054-3.CrossRefPubMedPubMedCentral

26.

Liu K, Ren T, Huang Y, Sun K, Bao X, Wang S, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 2017;8(8):e3015. https://doi.org/10.1038/cddis.2017.422.CrossRefPubMedPubMedCentral

27.

Zhu J, Wang S, Chen Y, Li X, Jiang Y, Yang X, et al. miR-19 targeting of GSK3beta mediates sulforaphane suppression of lung cancer stem cells. J Nutr Biochem. 2017;44:80–91. https://doi.org/10.1016/j.jnutbio.2017.02.020.CrossRefPubMed

28.

Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardio-Thorac Surg. 2009;36(3):446–53. https://doi.org/10.1016/j.ejcts.2009.03.063.CrossRef

29.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A. 2009;106(38):16281–6. https://doi.org/10.1073/pnas.0905653106.CrossRefPubMedPubMedCentral

30.

Kim S, Jang JY, Koh J, Kwon D, Kim YA, Paeng JC, et al. Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):462. https://doi.org/10.1186/s13046-019-1407-5.CrossRefPubMedPubMedCentral

31.

Ding J, Cheng XY, Liu S, Ji HY, Lin M, Ma R, et al. Apatinib exerts anti-tumour effects on ovarian cancer cells. Gynecol Oncol. 2019;153(1):165–74. https://doi.org/10.1016/j.ygyno.2019.01.010.CrossRefPubMed

32.

Deng M, Zha J, Zhao H, Jia X, Shi Y, Li Z, et al. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis. Exp Cell Res. 2020;390(1):111934. https://doi.org/10.1016/j.yexcr.2020.111934.CrossRefPubMed

33.

He X, Huang Z, Liu P, Li Q, Wang M, Qiu M, et al. Apatinib inhibits the invasion and metastasis of liver cancer cells by downregulating MMP-related proteins via regulation of the NF-kappaB signaling pathway. Biomed Res Int. 2020;2020:3126182.PubMedPubMedCentral

34.

Song YA, Ma T, Zhang XY, Cheng XS, Olajuyin AM, Sun ZF, et al. Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway. Cancer Cell Int. 2019;19(1):117. https://doi.org/10.1186/s12935-019-0836-8.CrossRefPubMedPubMedCentral

35.

Liu ZL, Jin BJ, Cheng CG, Zhang FX, Wang SW, Wang Y, et al. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(23):5370–7. https://doi.org/10.26355/eurrev_201712_13922.CrossRefPubMed

36.

Hu C, Zhu P, Xia Y, Hui K, Wang M, Jiang X. Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells. J Cancer Res Clin Oncol. 2018;144(7):1329–37. https://doi.org/10.1007/s00432-018-2667-8.CrossRefPubMed

37.

Watanabe H, Ichihara E, Kayatani H, Makimoto G, Ninomiya K, Nishii K, et al. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers. Cancer Sci. 2021;112(5):1853–64. https://doi.org/10.1111/cas.14801.CrossRefPubMedPubMedCentral

38.

Liu L, Qiao Y, Hu C, Liu Y, Xia Y, Wang L, et al. Endostatin exerts radiosensitizing effect in non-small cell lung cancer cells by inhibiting VEGFR2 expression. Clin Transl Oncol. 2016;18(1):18–26. https://doi.org/10.1007/s12094-015-1319-6.CrossRefPubMed

39.

Yang B, Wang Y, Chen Z, Feng YM, Shi LL. Effects of Apatinib on the “Stemness” of non-small-cell lung cancer cells in vivo and its related mechanisms. Can Respir J. 2020;2020:2479369.PubMedPubMedCentral

40.

Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, Kikuchi E, et al. CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol. 2014;19(2):254–9. https://doi.org/10.1007/s10147-013-0541-x.CrossRefPubMed

41.

Zhu JY, Yang X, Chen Y, Jiang Y, Wang SJ, Li Y, et al. Curcumin suppresses lung cancer stem cells via inhibiting Wnt/beta-catenin and sonic hedgehog pathways. Phytother Res. 2017;31(4):680–8. https://doi.org/10.1002/ptr.5791.CrossRefPubMed

42.

Zhou N, Zhang C, Liu D, Liu K, Wang G, Zhu H, et al. Apatinib in combination with S-1 as first-line treatment in patients with advanced metastatic gastric cancer: results from an open, exploratory, single-arm, phase ii trial. Oncologist. 2021;26(3):e374–e81. https://doi.org/10.1002/onco.13613.CrossRefPubMed

43.

Zheng B, Zhou C, Qu G, Ren C, Yan P, Guo W, et al. VEGFR2 promotes metastasis and PD-L2 expression of human osteosarcoma cells by activating the STAT3 and RhoA-ROCK-LIMK2 pathways. Front Oncol. 2020;10:543562. https://doi.org/10.3389/fonc.2020.543562.CrossRefPubMedPubMedCentral

44.

Tian ZC, Wang JQ, Ge H. Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling. J Orthop Translat. 2020;22:132–41. https://doi.org/10.1016/j.jot.2019.07.003.CrossRefPubMed

45.

Wen S, Shao G, Zheng J, Zeng H, Luo J, Gu D. Apatinib regulates the cell proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling. Pathol Res Pract. 2019;215(4):816–21. https://doi.org/10.1016/j.prp.2019.01.021.CrossRefPubMed

46.

Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, et al. beta-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 2003;63(12):3145–53.PubMed

47.

Hegde M, Guruprasad KP, Ramachandra L, Satyamoorthy K, Joshi MB. Interleukin-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors. J Biol Chem. 2020;295(34):12086–98. https://doi.org/10.1074/jbc.RA120.012590.CrossRefPubMedPubMedCentral

48.

Yang Y, Xia L, Wu Y, Zhou H, Chen X, Li H, et al. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer. Cancer Commun. 2021;41(6):511–27. https://doi.org/10.1002/cac2.12157.CrossRef

49.

Zhu J, Li X, Liang C, Zhou X, Ge M, Chen Y, et al. Apatinib suppresses lung cancer stem-like cells by complex interplay between beta-catenin signaling and mitochondrial ROS accumulation. Cell Death Discov. 2021;7(1):102. https://doi.org/10.1038/s41420-021-00480-6.CrossRefPubMedPubMedCentral

50.

Kim BH, Yi EH, Ye SK. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment. Arch Pharm Res. 2016;39(8):1085–99. https://doi.org/10.1007/s12272-016-0795-8.CrossRefPubMed

51.

Li F, Zhu T, Cao B, Wang J, Liang L. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer. 2017;84:184–92. https://doi.org/10.1016/j.ejca.2017.07.037.CrossRefPubMed

52.

Zhang Z, Zhang Y, Luo F, Ma Y, Fang W, Zhan J, et al. Dual blockade of EGFR and VEGFR pathways: results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. Clin Translat Med. 2020;10(2):e33. https://doi.org/10.1002/ctm2.33.CrossRef

53.

Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z, et al. Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706). J Thorac Oncol. 2021;S1556-0864(21)02177-8. https://doi.org/10.1016/j.jtho.2021.05.006.

54.

Zhang Z, Luo F, Zhang Y, Ma Y, Hong S, Yang Y, et al. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). Cancer Commun. 2019;39(1):69. https://doi.org/10.1186/s40880-019-0414-4.CrossRef

55.

Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409–16. https://doi.org/10.1093/annonc/mdv615.CrossRefPubMed

56.

Zhou ZJ, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4(2):203–8. https://doi.org/10.3978/j.issn.2218-6751.2015.03.02.CrossRefPubMedPubMedCentral

57.

Mohrherr J, Uras IZ, Moll HP, Casanova E. STAT3: versatile functions in non-small cell lung cancer. Cancers. 2020;12(5):1107.

58.

Teppo HR, Soini Y, Karihtala P. Reactive oxygen species-mediated mechanisms of action of targeted cancer therapy. Oxidative Med Cell Longev. 2017;2017:1485283.CrossRef

59.

Tang D, Ma J, Chu Z, Wang X, Zhao W, Zhang Q. Apatinib-induced NF-kappaB inactivation sensitizes triple-negative breast cancer cells to doxorubicin. Am J Transl Res. 2020;12(7):3741–53.PubMedPubMedCentral

60.

Nobrega-Pereira S, Caiado F, Carvalho T, Matias I, Graca G, Goncalves LG, et al. VEGFR2-mediated reprogramming of mitochondrial metabolism regulates the sensitivity of acute myeloid leukemia to chemotherapy. Cancer Res. 2018;78(3):731–41. https://doi.org/10.1158/0008-5472.CAN-17-1166.CrossRefPubMed

61.

Grillo E, Corsini M, Ravelli C, Zammataro L, Bacci M, Morandi A, et al. Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. Cancer Lett. 2021;507:80–8. https://doi.org/10.1016/j.canlet.2021.03.007.CrossRefPubMed

62.

Zhao J, Lin X, Meng D, Zeng L, Zhuang R, Huang S, et al. Nrf2 mediates metabolic reprogramming in non-small cell lung cancer. Front Oncol. 2020;10:578315. https://doi.org/10.3389/fonc.2020.578315.CrossRefPubMedPubMedCentral

63.

Hammad A, Namani A, Elshaer M, Wang XJ, Tang X. “NRF2 addiction” in lung cancer cells and its impact on cancer therapy. Cancer Lett. 2019;467:40–9. https://doi.org/10.1016/j.canlet.2019.09.016.CrossRefPubMed

64.

Jiang T, Harder B, Rojo de la Vega M, Wong PK, Chapman E, Zhang DD. p62 links autophagy and Nrf2 signaling. Free Radic Biol Med. 2015;88(Pt B):199–204.CrossRefPubMedPubMedCentral

Title: Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
Authors: Chunfeng Xie
Xu Zhou
Chunhua Liang
Xiaoting Li
Miaomiao Ge
Yue Chen
Juan Yin
Jianyun Zhu
Caiyun Zhong
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: NSCLC
Lung Cancer
Lung Cancer
NSCLC
Lung Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02069-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient‐derived primary culture case series in tridimensional and zebrafish models

Correction to: LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification

USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells

Underlying mechanisms and drug intervention strategies for the tumour microenvironment

Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine

Selective exosome exclusion of miR-375 by glioma cells promotes glioma progression by activating the CTGF-EGFR pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer